Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mitoxantrone
Drug ID BADD_D01480
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status approved; investigational
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D08224
MeSH ID D008942
PubChem ID 4212
TTD Drug ID D0R3JB
NDC Product Code 61703-343
UNII BZ114NVM5P
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H28N4O6
CAS Registry Number 65271-80-9
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Central nervous system lesion17.02.10.0110.000168%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Febrile bone marrow aplasia01.03.03.007; 08.05.02.0050.000112%Not Available
Infusion site phlebitis12.07.05.004; 08.02.05.003; 24.12.03.002--Not Available
Haemorrhage24.07.01.0020.000112%Not Available
Nail pigmentation23.02.05.007--Not Available
Blood alkaline phosphatase abnormal13.04.02.005--Not Available
Urine output13.13.03.003--Not Available
Antineutrophil cytoplasmic antibody decreased13.06.01.010--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Neurological symptom17.02.05.010--Not Available
Bladder disorder20.03.01.002--Not Available
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Ischaemia24.04.02.004--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Disease progression08.01.03.0380.000112%
Metastasis16.22.01.001--Not Available
Urine analysis abnormal13.13.02.008--Not Available
Transaminases abnormal13.03.04.034--Not Available
CD4 lymphocytes abnormal13.01.06.035--Not Available
Bone marrow failure01.03.03.005--
Oral disorder07.05.01.0050.000112%Not Available
Cutaneous coccidioidomycosis23.11.03.004; 11.03.09.002--Not Available
Acute kidney injury20.01.03.016--
Systemic infection11.01.08.050--Not Available
Superficial spreading melanoma stage unspecified23.08.01.010; 16.03.01.0100.000112%Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene